Mitsui Chemicals (4183) Q4 2025 earnings summary

Executive summary

• Fiscal year 2024 operating income before special items rose 5% year-on-year to JPY 101.0 billion, driven by specialty chemicals growth, price revisions, and business restructuring, offsetting the Osaka ethylene plant failure.

• Net income attributable to owners of the parent declined by 35.5% year-on-year to JPY 32.2 billion, mainly due to impairment losses, higher tax expenses, and financial losses.

• Sales revenue for fiscal year 2024 increased 3.4% year-on-year to JPY 1,809.2 billion, supported by higher selling prices and favorable exchange rates.

• Actual FY2024 results fell short of forecasts due to lower ICT Solutions sales, impairment losses in Life & Healthcare Solutions, and higher income tax expenses.

• Strategic investments continued in R&D, capacity expansions, and business restructuring, including new plant construction and product launches.

Financial highlights

• Gross profit improved to JPY 388.3 billion from JPY 370.8 billion year-on-year.

• Free cash flow was positive at JPY 35.5 billion, with record-high operating cash flows of JPY 200.5 billion.

• Total assets decreased by JPY 61.8 billion to JPY 2,154.0 billion, mainly due to business restructuring and repayments.

• Basic earnings per share fell to JPY 170.56 from JPY 262.99 year-on-year.

• Cash and cash equivalents at year-end decreased to JPY 170.6 billion.

Outlook and guidance

• Fiscal year 2025 sales revenue is forecast at JPY 1,770.0 billion, a decrease of 2.2% year-on-year.

• Operating income before special items is projected to rise 9% to JPY 110.0 billion.

• Net income attributable to owners of the parent is expected to increase 70.6% to JPY 55.0 billion.

• Free cash flow for fiscal year 2025 is expected to be positive JPY 45.0 billion.

• Annual dividend outlook maintained at JPY 150 per share, with potential for increase depending on business and policy developments.